Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 11/20 | 0.45 |
| ▸ | GRM5 | P41594 | 2/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.40 |
| ▸ | HRH1 | P35367 | 4/20 | 0.40 |
| ▸ | HTR2B | P41595 | 4/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2060043 | 0.84 | RIPK1 (0.52) | MCHR1GRM5ADRA2AHRH1HTR2B | |
| SCHEMBL2060124 | 0.82 | RIPK1 (0.47) | MCHR1GRM5ADRA2AHRH1HTR2B | |
| SCHEMBL2060253 | 0.82 | RIPK1 (0.48) | MCHR1GRM5RIPK1MAPK14SMN1; SMN2 | |
| SCHEMBL885700 | 0.82 | RIPK1 (0.53) | MCHR1GRM5ADRA2AHRH1HTR2B | |
| SCHEMBL885793 | 0.77 | RIPK1 (0.42) | MCHR1GRM5RIPK1RAB9ASMN1; SMN2 | |
| SCHEMBL885592 | 0.77 | KDR (0.48) | MCHR1TAS1R3TAS1R1TAS1R2RIPK1 | |
| SCHEMBL2060136 | 0.77 | MCHR1 (0.46) | MCHR1GRM5ADRA2AHRH1HTR2B | |
| SCHEMBL885847 | 0.76 | RIPK1 (0.48) | MCHR1GRM5RIPK1SMN1; SMN2SMYD3 | |
| SCHEMBL885585 | 0.72 | RIPK1 (0.45) | MCHR1ADRA2ARIPK1 | |
| SCHEMBL2060036 | 0.69 | GRM5 (0.49) | MCHR1GRM5ADRA2AHRH1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081928-B1 | Pyrrolo-pyridine kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-02-26 | — | — | EP | claimed |
| CN-101600714-B | Novel pyrindole kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2013-08-21 | — | — | CN | claimed |
| US-8148361-B2 | Kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | claimed |
| US-20100041636-A1 | NOVEL KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-18 | — | — | US | claimed |
| CN-101600714-A | Novel kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-12-09 | — | — | CN | claimed |
| EP-2081928-A2 | PYRROLO-PYRIDINE KINASE INHIBITORS | Brystol-Myers Squibb Company (US) | 2009-07-29 | — | — | EP | claimed |
| WO-2008060907-A2 | PYRROLO-PYRIDINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-22 | — | — | WO | claimed |
| EP-2081928-B1 | Pyrrolo-pyridine kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-02-26 | — | — | EP | disclosed |
| CN-101600714-B | Novel pyrindole kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2013-08-21 | — | — | CN | disclosed |
| US-8148361-B2 | Kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-20100041636-A1 | NOVEL KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-18 | — | — | US | disclosed |
| CN-101600714-A | Novel kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-12-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041636-A1 | NOVEL KINASE INHIBITORS | IGF1R, FGFR1, FLT1 | MCHR1 1197/4885GRM5 2155/4885ADRA2A 3276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.